Expert Outlook: Pacific Biosciences Through The Eyes Of 10 Analysts
Portfolio Pulse from Benzinga Insights
Pacific Biosciences (NASDAQ:PACB) has been analyzed by 10 analysts, showing a shift towards a more cautious outlook with recent ratings leaning towards neutral. The average 12-month price target has been significantly lowered from $8.90 to $4.4, reflecting a 50.56% decline and indicating a bearish sentiment. Analysts from firms like Piper Sandler, Barclays, and Goldman Sachs have adjusted their price targets downwards in response to market dynamics and company performance. Despite positive revenue growth of 113.35% as of December 31, 2023, Pacific Biosciences faces challenges in profitability and efficient capital utilization, with a net margin of -140.55% and ROE of -11.2%.
May 13, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pacific Biosciences faces a bearish outlook from analysts, with a significant reduction in the average 12-month price target and a shift towards neutral ratings. Despite strong revenue growth, profitability and capital efficiency issues persist.
The downward revision of price targets and the predominance of neutral ratings reflect growing concerns among analysts about Pacific Biosciences' future performance. Despite the company's impressive revenue growth, its poor profitability metrics and high debt levels are likely to dampen investor sentiment in the short term. The significant reduction in the average price target suggests that analysts see fewer upside potentials, which could lead to a negative impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100